The function of the Fanconi anemia group C protein (FANCC) is still unknown, though many studies point to a role in damage response signaling. Unlike other known FA proteins, FANCC is mainly localized to the cytoplasm and is thought to act as a messenger of cellular damage rather than an effector of repair. FANCC has been shown to interact with several cytoplasmic and nuclear proteins and to delay the onset of apoptosis through redox regulation of GSTP1. We investigated the fate and function of FANCC during apoptosis. Here we show that FANCC undergoes proteolytic modification by a caspase into a predominant 47-kDa ubiquitinated protein fragment. Lack of proteolytic modification at the putative cleavage site delays apoptosis but does not affect MMC complementation. These results suggest that FANCC function is regulated through proteolytic processing.
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Fanconi anemia (FA)
1 is a genetic disease identified as a bone marrow failure syndrome associated with cancer susceptibility, congenital defects, and cellular sensitivity to DNA cross-linking agents (1) . FA patients are distributed into at least nine complementation groups. Eight FA genes have been cloned, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, and FANCL, and recently the breast cancer susceptibility gene, BRCA2, has been assigned to complementation group D1 and possibly to group B, although the latter requires confirmation (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Since a defect in any of the nine possible FA genes leads to a similar clinical phenotype, FA proteins appear to act in a common pathway to the breast cancer susceptibility proteins BRCA1 and BRCA2 sequentially and/or as a multiprotein complex.
Several studies have shown that five of eight known FA proteins, FANCA, FANCC, FANCE, FANCF, and FANCG, bind to each other and form a multiprotein complex that translocates to the nucleus (12) (13) (14) (15) (16) (17) (18) . Assembly of the multiprotein complex seems to be necessary for the activation through posttranslational monoubiquitination of FANCD2 (19, 20) . Monoubiquitination of FANCD2 is dependent on the recently identified FANCL gene that possesses ubiquitin ligase activity (11) . The FANCD2 protein has been associated in nuclear foci with BRCA1, suggesting that BRCA1 may be a downstream component of the FA molecular pathway. Recently, the BRCA1 protein was shown to interact with the FANCA protein supporting a role of BRCA1 in the Fanconi pathway (21) .
The FA group D1 protein, BRCA2/FANCD1/FANCB, may function upstream in the pathway by promoting the formation of the FA complex and/or downstream by transducing signals from FA proteins to the DNA repair machinery. Mutation in one of the FA genes abolishes the FA complex formation, the monoubiquitination of FANCD2 and the nuclear foci formation in response to genotoxic stress. Nuclear localization of the FA complex was found to be critical for cellular resistance to MMC (17, 22) . However, several lines of investigation have suggested additional extranuclear functions for at least some FA components. For instance, FANCC and FANCG were shown to bind non-nuclear proteins involved in oxygen radical metabolism such as cytochrome P450 reductase, glutathione S-transferase P1, or cytochrome P450 2E1 (23) (24) (25) . Of all known FA proteins, FANCC is the only protein predominantly located in the cytoplasm although a fraction is located to the nucleus in association with the FA protein complex (26) . The nuclear accumulation of FANCC seems to be mediated by FANCE (27) . FANCC was also shown to bind protein chaperones GRP94 and HSP70 (28, 29) . In addition, FANCC was shown to form protein complexes with other partners such as cdc2, involved in cell cycle regulation (30) , the transcription factors FAZF (31) and STAT1 (32) and the protein scaffold, ␣-spectrin II (33, 34) . Studies on FANCC protein structure have shown evidence that FANCC has multifunctional roles in cell survival, uncoupling the MMC complementation function and growth factor signaling (35) . Also, FA complementation group C cells and Fancc Ϫ/Ϫ cells derived from the FA group C mouse model show an increased apoptosis response to various cytokines (TNF␣, IFN␥, MIP-1␣) and DNA-damaging agents such as MMC or ␥-rays (36 -38).
Overexpression of FANCC was shown to delay the onset of apoptosis induced by various signals, including Fas activation, serum deprivation, and MMC (39, 40) , via the redox regulation of GSTP1 activity (24) . However the exact role of FANCC in the FA molecular pathway is still unknown.
Here we show that FANCC undergoes proteolytic modification by a caspase during apoptosis. FANCC cleavage occurs in FA cell lines from all complementation groups tested. Mutagenesis of the putative cleavage site does not interfere with the FA complex formation or with MMC complementation function, although absence of FANCC proteolytic processing delays the onset of apoptosis.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture Conditions-Normal (HSC93) and FA Epstein-Barr virus (EBV)-transformed lymphoblasts (EUFA173, FA-A; HSC230, FA-B; HSC536, FA-C; HSC62, FA-D1; EUFA130, FA-E; EUFA121, FA-F) were grown at 37°C, 5% CO 2 in RPMI 1640 media supplemented with 15% fetal calf serum. HEK293T cells were grown at 37°C, 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Cells were maintained in log phase growth before setting up experiments. FA-C lymphoblastoid cells were transfected by electroporation and HEK293T cells were transfected by the calcium phosphate transfection method with either the pFAC3 plasmid (pFANCC) containing the full-length FANCC gene (2) or FANCC constructs (see below). Transfected cells were grown in hygromycin B (200 ng/ml) to select for plasmid-containing cells. MMC sensitivity was assayed by plating cells at a density of 1 ϫ 10 5 per ml in 24 wells plate. Twenty-four hours after plating, various concentrations of MMC were added, and cells were further cultured for 5-7 days. Growth inhibition was evaluated by counting the number of cells in each well using an automated cell counter (Counter Z series, Beckman Coulter). Percent viability was established as the number of cell grown in drug divided by the number of cells grown in media alone. For proteasome and apoptosis inhibition or induction, cells were grown as previously indicated and drugs were added for various stimulation periods. Inhibitors were resuspended either in water or Me 2 SO and used as follows: proteasome inhibitors ALLN at 50 M, lactacystin at 10 M and MG132 at 10 M (all from Biomol Laboratories Inc); lysosomal inhibitor E64 at 50 M; apoptosis inducer etoposide at 68 M (Sigma), staurosporine at 1 M (Roche Applied Science); caspase inhibitors, YVAD-CHO, IETD-CHO, DEVD-CHO (100 M final; Bachem) were added 30 min prior to proteasome inhibition. Controls were either performed with equivalent volumes of water or Me 2 SO.
Mutagenesis and FANCC Constructs-Mutagenesis of both FANCC LETD and KEMD putative caspase sites were performed by PCR using FANCC-specific primers containing the nucleotide change from an adenine to a cytosine changing in both cases the aspartic acid to an alanine at codon 56 (FANCC-D56A) or 306 respectively (FANCC-D306A). PCR amplifications were performed using a proofreading polymerase (Roche Diagnostics) with the following conditions: 1 cycle at 94°C 5 min, followed by 35 cycles of 94°C for 30 s, 55°C 30 s and 72°C for 30 s. PCR fragments were gel-purified and cloned into expression vectors pRep4 or pEBV (Invitrogen). The FANCC-del-1-18 (1-18-bp deletion of FANCC open reading frame) mutant was produced from a BglII restriction digest at position 273 of the full-length FANCC cDNA coding for a polypeptide missing the first 7 amino acids. All clones were sequenced to confirm the presence of the base change at the putative caspase site and to confirm the absence of PCR-induced mutations. FANCC cDNA constructs were cloned in fusion with either EGFP in pEGFPC1 vector (Clontech; full-length FANCC, pEGFPFANCC; FANCC from amino acids 56 -558, pEGFPFANCC-56 -558 and C-terminal FANCC from amino acids 306 -558, pEGFPFANCC-306 -558) or His tag at the N-terminal or C-terminal end (pEBVFANCC and pFANCCHis in pEBVHis or pREP4 vectors, respectively; Invitrogen).
Western Blotting Analysis and Immunoprecipitations-Total cell lysates were prepared in SDS loading buffer (50 mM Tris-HCL, 2% 2-mercaptoethanol, 2% SDS). Samples were sonicated and boiled and subjected to electrophoresis on a 10% SDS-acrylamide gel (Invitrogen). Proteins were electrotransferred onto a polyvinylidene difluoride membrane (Amersham Biosciences) and probed with either polyclonal antipoly(ADP) ribose polymerase (PARP) antibodies (Dr. Guy Poirier, Qué-bec, Canada), anti-presenilin-1 (PS1) antibodies, polyclonal anti-His antibodies (Santa Cruz Biotechnology), or anti-human FANCC antibodies raised against the N-terminal or C-terminal end of the protein, followed by horseradish peroxidase-conjugated goat anti-rabbit IgG or rabbit anti-mouse IgG (Santa Cruz Biotechnology). Chemiluminescence was detected by autoradiography using the ECL Western blotting analysis system from Amersham Biosciences. For immunoprecipitation, 5 ϫ 10 6 to 1 ϫ 10 7 cells were harvested, washed in phosphate-buffered saline, and resuspended in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, and complete proteases inhibitors; Roche Diagnostics). Lysates were cleared by centrifugation and mixed with 5 g of the precipitating antibodies: anti-FANCC, anti-Myc (Santa Cruz Biotechnology), or anti-HA (Roche Diagnostics). After overnight incubation at 4°C, protein A-agarose beads were added to each sample and incubated for 2 h at 4°C with gentle agitation. Beads were washed three times and resuspended in SDS loading buffer, boiled, and loaded immediately on denaturing 10% SDS-PAGE gels. Proteins were transferred and visualized as described above.
Polyclonal anti-FANCC antiserum was generated in rabbits using as immunogens peptides corresponding to FANCC residues 41-58 and 544 -558 coupled via the N-terminal cysteine residue to the carrier protein keyhole limpet hemocyanin (KLH). New Zealand White female rabbits were injected subcutaneously with a mixture of 2 mg (0.5 ml) of peptide and 0.5 ml of Freund's complete adjuvant and boosted three times at 4-week intervals. FANCC antibodies were affinity-purified using Amminolink plus affinity columns (Pierce). The animal experiments were approved by the Animal Care committee of the Université Laval.
Detection of Ubiquitination-HEK293T cells were transiently transfected with 10 g of full-length FANCC (pFAC3) along with 10 g of an HA-tagged ubiquitin-expressing vector (a gift from Dr. Shigetsugu Hatakeyama, Kyushu University, Higashi-Ku, Fukuoka, Japan) by the calcium phosphate transfection method. Following an overnight incubation period, cell media was changed, and cells were treated with the proteasome inhibitor ALLN (50 M). Total cell lysates were prepared, subjected to SDS-PAGE electrophoresis and probed with either anti-HA antibodies (clone 12CA5, Roche Applied Science) or anti-FANCC antibodies as described above.
Fluorescence Microscopy-Hela or HEK293T cells were grown on microscopy glass cover slides in 6-well plates and transfected with pEGFP-FANCC fusion vectors using the calcium phosphate precipitation method. 24 -48 h after transfection, cells were washed in phosphate-buffered saline, fixed in 2% paraformaldehyde in phosphatebuffered saline, stained with DAPI, and mounted on microscopic slides. Cells were visualized using an inverted epifluorescence microscope (Nikon Canada Inc.), and images were captured using a Coolsnap digital camera (Canberra-Packard-Canada).
RESULTS
Proteolytic Modification of FANCC-It has been reported previously that the FANCC protein is regulated at the posttranscription level in a cell cycle-dependent manner (41) . While Heinrich et al. (41) reported that FANCC regulation occurred both at the mRNA translation and protein degradation level, we observed that FANCC was regulated through proteolytic modification before being targeted to the 26 S proteasome pathway (Fig. 1) . Western blot analysis of protein extracts from normal cells incubated with the irreversible or reversible proteasome inhibitors, lactacystin, and ALLN, respectively, showed accumulation of a truncated FANCC protein fragment (Fig. 1) . No accumulation of the full-length endogenous FANCC protein was observed in either ALLN-or lactacystin-treated cells. Proteasome inhibitors have been shown to induce apoptosis (42, 43) . Detection of a 47-kDa FANCC fragment (FANCCp47) correlated with apoptosis induction as demonstrated by PARP cleavage and caspase-3 and caspase-8 activation (Fig. 1C) . These results suggest that during apoptosis the FANCC protein undergoes proteolytic cleavage before being targeted to the 26 S proteasome pathway. We also tested whether FANCC proteolytic modification was only detectable with inhibitors specific to the 26 S proteasome degradation pathway. We used the lysosomal inhibitor E-64 and analyzed FANCC cleavage. The lysosomal inhibitor E-64 did not induce apoptosis as shown by lack of PARP cleavage and, consequently, we did not observe any FANCC proteolytic fragments as compared with proteasome inhibitors ALLN, lactacystin or MG132 (Fig. 1D) . To determine if FANCC cleavage resulted specifically from apoptosis induction we used the fast-acting apoptotic inducer staurosporine and analyzed for FANCC cleavage. Cells were treated with staurosporine with or without the proteasome inhibitor ALLN. Staurosporine was added 1 h prior to proteasome inhibition. Using these conditions, the proteasome inhibitor ALLN did not induce apoptosis showed by lack of caspase-3 and caspase-8 activation or PARP cleavage (Fig. 1E) . However, staurosporine alone or in combination with ALLN induced apoptosis shown by caspase-3 and caspase-8 activation and PARP cleavage while FANCC 47-kDa fragment was only detectible when ALLN was used in conjunction with staurosporine. These results suggest that cleavage of FANCC is a direct consequence of apoptosis and that proteasome inhibition is required for FANCCp47 detection.
FANCC Is Cleaved by a Caspase-Since caspases have been shown to be important mediators of apoptosis, cleavage of FANCC may occur by a caspase. To verify if the 47-kDa FANCC-specific fragment resulted from a cleavage by a caspase, we incubated normal HSC93 lymphoblastoid cells with different caspase inhibitors for group I (Ac-YVAD-CHO), group II (Ac-DEVD-CHO) and group III caspases (Ac-IETD-CHO) (44) . These inhibitors have been shown to block various forms of apoptosis by binding as substrates to the catalytic site of caspases, where Ac-YVAD-CHO preferentially inhibits Group I caspases such as caspase-1, -4, and -5, and to a lesser extent some members of Group III caspases including caspase-6, -8, and -10 (44). Ac-DEVD-CHO is a potent inhibitor of caspase-3 and -7 and, to a lesser extent of caspase-8, whereas Ac-IETD-CHO resembles the preferred sequences for Group III caspases (caspase-6, -8, -9, and -10). Cells were treated with caspase inhibitors 30 min prior to the addition of the proteasome inhibitor lactacystin. Western blot analysis of protein extracts, using FANCC-specific antibodies, revealed that all caspase inhibitors prevented FANCC cleavage and only little FANCC p47 could be detected (Fig. 2) . Inhibition of caspase activity was confirmed by reduced PARP cleavage and absence of the caspase-3 12-kDa fragment. Similar results were ob- 
of ALLN. Apoptosis induction was measured by Western blotting using anti-caspase-8 and anti-caspase-3 and anti-PARP antibodies. FANCC cleavage profile was analyzed by immunoblotting using anti-FANCC antibodies specific for the C-terminal end of FANCC.
FIG. 2. Caspases inhibition prevents FANCC cleavage.
Normal HSC93 lymphoblastoid cells were incubated with or without the irreversible proteasome inhibitor lactacystin (10 M) for 16 h. Caspase inhibitors, YVAD, DEVD, and IETD (100 M) were added 30 min prior to the addition of lactacystin. The FANCC cleavage profile was analyzed by Western blotting using anti-FANCC antibodies specific for the C-terminal end of FANCC. Apoptosis was analyzed using anti-PARP or anti-caspase-3 antibodies. tained using the reversible proteasome inhibitor ALLN (data not shown).
Mapping of the FANCC Cleavage Site-To identify the FANCC putative cleavage site, we first investigated if the 47-kDa FANCC fragment corresponded to the N-or C-terminal end of the FANCC protein. Using specific FANCC antibodies directed against either the N-or C-terminal end of the protein, we show that FANCCp47 corresponds to the C-terminal end of the protein (Fig. 3A) . Similar results were obtained with FANCC fusion proteins His-tagged at the N or C terminus and probed with anti-His antibodies (Fig. 3B) . The p47 FANCC fragment was detected from both endogenous or overexpressed FANCC. However, overexpression of FANCC resulted in the presence of a 55-kDa FANCC-specific band detected with anti-FANCC antibodies directed against the C-terminal end of the protein. This 55-kDa truncated FANCC protein could be the result of a reinitiation from methionine 55 as previously reported (45 resemble preferred cleavage sites for Caspase-8 (46) . Although, estimation of a FANCC fragment size at these putative caspase sites do not give a C-terminal 47-kDa fragment size, mutagenesis of the two most plausible FANCC cleavage sites was performed where the aspartic acid at position 56 or 306 was mutated to the noncleavable amino acid alanine (D56A and D306A, respectively). Cells were transiently transfected with pFANCC-D56A or pFANCC-D306A and subjected to proteasome inhibition in order to determine if FANCC cleavage
FIG. 3. Proteolytic modification of FANCC reveals a C-terminal fragment.
Normal HEK293T cells were transiently transfected with either the empty vector pRep4 or plasmids coding for N-terminal or C-terminal His-tagged full-length FANCC (pEBVFANCC and pFANCCHis, respectively). Transfected cells were incubated for 16 h with the proteasome inhibitor ALLN (50 M). Total cell lysates were prepared and resolved on SDS-PAGE gels. Immunoblotting was performed using anti-FANCC antibodies specific for either the N-or C-terminal end of the FANCC protein (A) or anti-histidine-specific antibodies (B). C, normal HEK293T cells transfected with either empty pRep4 vectors, full-length wild-type FANCC (pFANCC) or KEMA and LETA mutated FANCC (pFANCC-D56A and pFANCC-D306A, respectively) and probed with anti-FANCC-specific antibodies. D, FA group C lymphoblastoid cells HSC536 were stably transfected with either full-length wild-type FANCC or DVSD-truncated FANCC (pFANCC-del1-18). NS, nonspecific bands. E, normal HEK293T cells were transiently transfected with both the HA-tagged ubiquitin expression vector and full-length FANCC (pFANCC). Transfected cells were incubated for 16 h with the proteasome inhibitor ALLN (50 M). Total cell lysates were prepared and resolved on SDS-PAGE gels. Immunoblotting was performed using anti-HA or anti-FANCC antibodies specific for the C-terminal end of the FANCC protein. F, normal HEK293T cells were transiently transfected with either or both the HA-tagged ubiquitin expression vector (pHAub) and full-length FANCC (pFANCC). Transfected cells were incubated for 16 h with the proteasome inhibitor ALLN (50 M). Total cell lysates were prepared and resolved on SDS-PAGE gels. Immunoblotting was performed using anti-HA antibodies.
occurred at either site. Replacement of both Asp-56 and Asp-306 with Ala resulted in the absence of proteolytic processing of FANCC, thus eliminating p47 (Fig. 3C) . We also performed analysis of the DSVD putative cleavage site (pFANCC-del1-18) using FA-C mutant cells transfected with the full-length or truncated FANCC and showed that the DSVD FANCC deletion mutant was cleaved into p55 and p47 FANCC fragments (Fig. 3D) . Since FANCC proteolytic processing give rise to an observed fragment size of 47 kDa and the putative caspase site at Asp-306 gives a predicted size of 28 kDa, suggest that the FANCC proteolytic fragment may be subjected to post-translational modification such as ubiquitination. Furthermore, since we only observed FANCCp47 with proteasome inhibitors, we tested the hypothesis that FANCC proteolytic fragment is ubiquitinated before being targeted to the proteasome. To do so, we transfected HEK293T cells with a cDNA encoding HA-ubiquitin (47) along with full-length FANCC and subjected cells to proteasome inhibition. We found that the FANCC p47 fragment observed following proteasome inhibition is ubiquitinated (Fig. 3E) . Ubiquitin was only detectible in cells transfected with the HA-ubiquitin coding vector (pHAub) alone or in combination with the full-length FANCC coding vector pFANCC (Fig. 3F) .
The FANCC C-terminal Fragment Is Located Principally in the Cytoplasm-The FANCC protein has been shown to be distributed principally to the cytoplasm but also to the nucleus (26) . To address the question whether the C-terminal proteolytic FANCC fragment is also located to the cytoplasm, we evaluated the subcellular localization of the FANCC C-terminal fragment using EGFP fusion constructs. Full-length and C-terminal FANCC were cloned in fusion to the EGFP protein, transfected into HEK293T cells and visualized by fluorescence microscopy (Fig. 4) . All FANCC constructs, either full-length FANCC, FANCC corresponding to amino acids 56 -558 (pFANCC-56 -558) or C-terminal FANCC (pFANCC-306 -558), were found to be principally located to the cytoplasm. We also employed a differential centrifugation technique in order to obtain subcellular fractions. We found that the endogenous proteolytic p47 FANCC fragment is located to the cytoplasm in ALLN-treated cells (data not shown).
FANCC Proteolytic Modification Occurs in All FA Cell Lines Tested and Absence of Cleavage Does Not Affect the FA Complex
Formation-We evaluated if mutations in one of the FA genes would abolish FANCC proteolytic processing. Western blot analysis of protein extracts from FA complementation group A, B, D1, E, and F cell lines showed that mutation in one of the FA genes did not affect FANCC proteolytic modification (Fig. 5A) . Endogenous FANCC p47 was detectable in all FA cell lines tested. In addition, the FANCC L554P mutation found in FA-C HSC536N cells did not interfere with the proteolytic processing of the FANCC protein. As expected, the proteasome inhibitor ALLN induced apoptosis in all FA cell lines tested as demonstrated by PARP cleavage (Fig. 5A ) and caspase-3 activation (data not shown). We also tested whether lack of proteolytic processing of FANCC would influence FA complex formation. We transfected the FANCC caspase site mutant FANCC-D306A into HEK293T or FA-C cells and evaluated FA complex formation by FANCC interaction with FANCE and by the monoubiquitination of FANCD2. Western blot analysis of immunoprecipitation products revealed that FANCC D306A mutants can be co-immunoprecipitated with FANCE (Fig. 5B) . We also found that the FANCC D56A putative cleavage site mutant could be immunoprecipitated with FANCE (data not shown). Immunoprecipitation using antibodies directed against His-tagged FANCC could also immunoprecipitate FANCE (data not shown). Furthermore, monoubiquitination of FANCD2 could be observed in FA-C cells transfected with both FANCC D56A and D306A caspase site mutants (data not shown). These results suggest that FANCC proteolytic processing occurs independently of the FA complex and that lack of proteolytic processing does not interfere with the FA complex formation.
Caspase-resistant FANCC Delays the Onset of Apoptosis but Does Not Affect Its MMC Complementation
Function-To evaluate the significance of FANCC proteolytic processing on the characteristic MMC hypersensitivity of FA cells, aspartic-acid FANCC mutants D56A and D306A and the FANCC 1-18 deletion mutant were stably transfected into FA-C HSC536N cells and complementation analysis were performed. FANCC noncleavable mutants, pFANCC-del1-18, pFANCC-D56A, and pFANCC-D306A, conferred MMC resistance in FA-C cells as did the normal FANCC cDNA. We also tested the complementation function of FANCC proteolytic fragments corresponding to either the N-terminal end of FANCC (amino acids 2-306; pFANCC-2-306), the C-terminal end corresponding to the putative p47 fragment (amino acids 306 -558; pFANCC-306 -558) and the internal FANCC fragment from amino acids . Overexpression of these FANCC fragments did not complement the MMC hypersensitivity of FA-C cells (Fig. 6B) . In addition, the C-terminal-transfected cells seemed to be more sensitive to MMC than the untransfected cells suggestive of a proapoptotic function of the FANCC C-terminal fragment. We also examined the effect of the Asp-306 cleavage site mutant on apoptosis. Since cleavage of proteins occurs either to activate or inactivate their functions, we evaluated the effect of uncleavable FANCC on apoptosis. We show that lack of proteolytic processing of FANCC-D306A resulted in a delay in apoptosis induction as seen by caspase-3 and caspase-8 activation and PARP cleavage (Fig. 6C) .
DISCUSSION
This is the first report of proteolytic regulation of a member of the Fanconi anemia family of proteins. Fanconi anemia proteins are known to function as a multimeric protein complex that translocates to the nucleus although the exact role of this complex or of each protein member has yet to be determined. Recently, FA proteins have been associated with the BRCA molecular pathway linking their role in molecular processes of DNA repair (19, 21) .
Many proteins involved in DNA damage signaling or repair are regulated through the action of cysteine-proteases or caspases such as PARP, human RAD51 and DNA-PK (48 -52).
Here, we present evidence that one of the FA proteins, FANCC is regulated by proteolytic modification, giving rise to a Cterminal 47-kDa fragment. We also show that caspase inhibitors prevent FANCC proteolytic processing into the p47 Cterminal fragment, suggesting that FANCC cleavage occurs through the activity of a caspase. FANCC expression has been previously shown to be regulated at the post-transcriptional level possibly through altering its mRNA translation and/or controlling its degradation (41) . We demonstrate here that FANCC is regulated through proteolytic processing by a caspase during apoptosis. Although analysis of the FANCC protein sequence revealed 4 putative caspase-like cleavage sites, our results demonstrate cleavage of the protein at position 56 (KEMD2S) and at position 306 (LETD2G) giving rise to a 55-kDa protein fragment and to the C-terminal 47-kDa FANCC fragment. Furthermore, both cleavage site mutants FANCC-D56A and FANCC-D306A showed an absence of FANCC proteolytic processing. In addition, the 55-kDa FANCC fragment may not result from reinitiation at Met-55, as previously suggested (45) , since overexpression of the cleavage site mutant containing an intact methionine did not produce the 55 kDa protein. We therefore propose that FANCC is cleaved at both KEMD and LETD sites giving rise to a 55-kDa fragment and the p47 FANCC C-terminal protein. Cleavage at both Asp56 and Asp306 would also produce an internal FANCC fragment of 249 amino acids (amino acids 56 -306); however, this fragment cannot be detected with the available anti-FANCC antibodies.
Interestingly, the observed C-terminal FANCC fragment molecular weight of ϳ47-kDa differs from the predicted size of a cleavage at Asp-306, suggesting that FANCC may be subjected to post-translational modification. Since polyubiquitination is a marker for protein degradation and is used to target proteins to the 26 S proteasome (53) and that visualization of the cleaved FANCCp47 protein fragment is only possible through inactivation of the 26 S proteasome machinery, this suggested that cleaved FANCCp47 is quickly targeted for degradation through polyubiquitination. Our results demonstrate that FANCCp47 is ubiquitinated, either polyubiquitinated or doubly ubiquitinated, after cleavage. Since the newly identified FA gene, FANCL, possesses ubiquitin ligase activity (11), FANCCp47 may be ubiquitinated by the FANCL protein. Further experiments will need to be conducted to validate this hypothesis.
The FANCC protein has been associated with a role as suppresor of apoptosis (38, 39) . Rathbun et al. (54) have also proposed that FANCC suppresses apoptotic responses to IFN-␥ through a direct or indirect action upstream of caspase-3 activation. Using caspase inhibitors Ac-YVAD-CHO, Ac-DEVD-CHO, or Ac-IETD-CHO, the FANCCp47 proteolytic fragment could not be detected. Since these caspase inhibitors, specific for Groups I, II, and III, respectively, inhibit FANCC processing, this suggests that FANCC proteolytic modification may likely occur by a caspase. In addition, both FANCC KEMD2S and LETD2G putative cleavage sites are composed of residues known to be caspase-8-preferred substrates (46) and possess small residues at the P1Ј cleavage position such as serine and glycine consistent with caspases, including caspase-8, subsite preferences (55) . Furthermore, the LETD2G cleavage site resembles both procaspase-3 and BID cleavage sites that are cleaved by caspase-8 (56 -58), therefore, cleavage of FANCC could occur by caspase-8. However, since all caspase inhibitors used inhibited FANCC processing, it is difficult to identify a Whole cell extracts were prepared as described under "Experimental Procedures" and resolved on SDS-PAGE gels. FANCC proteolytic processing was analyzed by immunoblotting using C-terminal-specific anti-FANCC antibodies. Apoptosis was analyzed using anti-PARP antibodies. B, co-immunoprecipitation was performed using HEK293T cells transiently transfected with either wild-type or caspase-site mutant FANCC (pFANCCHis and pFANCC-D306A) with or without FANCE (pFANCE). Immunoprecipitations were done using antibodies directed against myc-FANCE fusion protein. Whole cell extracts (WCE) and immunoprecipitates were prepared as described under "Experimental Procedures" and resolved on SDS-PAGE gels and revealed using either anti-His or anti-Myc tag antibodies. specific caspase responsible for FANCC cleavage.
Lack of proteolytic processing of FANCC does not interfere with the FA complex formation or its ability to complement MMC in FA-C cells. These results suggest that proteolytic modification of FANCC is not required for its function in DNA repair or DNA damage signaling but support the idea that cleavage of FANCC may inhibit its suppressor of apoptosis function or activate a proapoptotic ability. Proteolytic modification of proteins through caspase activity results either in activation of proteins such as zymogens (pro-caspases) or inactivation of their function (52) . We showed that lack of proteolytic processing delays the onset of apoptosis as shown by caspase 3 or 8 activation and PARP cleavage (Fig. 6C) . Thus, FANCC proteolytic modification may inactivate a FANCC protective function. To determine whether the C-terminal FANCC fragment has a proapoptotic function will require further studies.
